Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 17/20 | 0.48 |
| ▸ | INSR | P06213 | 15/20 | 0.48 |
| ▸ | IGF1R | P08069 | 15/20 | 0.48 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | ROS1 | P08922 | 1/20 | 0.42 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30223498 | 1.00 | ALK (0.48) | ALKINSRIGF1RMAP4K1AURKA | |
| SCHEMBL29172320 | 0.86 | ALK (0.42) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL30875688 | 0.86 | ALK (0.45) | ALKINSRIGF1RMAP4K1AURKA | |
| SCHEMBL25339059 | 0.86 | ALK (0.45) | ALKINSRIGF1RMAP4K1AURKA | |
| SCHEMBL30183996 | 0.84 | ALK (0.46) | ALKINSRIGF1RMAP4K1AURKA | |
| SCHEMBL25338974 | 0.84 | ALK (0.46) | ALKINSRIGF1RMAP4K1AURKA | |
| SCHEMBL23932620 | 0.83 | ALK (0.53) | ALKINSRIGF1RMAP4K1AURKA | |
| SCHEMBL23933001 | 0.82 | INSR (0.47) | ALKINSRIGF1RMAP4K1AURKA | |
| SCHEMBL30487106 | 0.82 | ALK (0.48) | ALKINSRIGF1RMAP4K1AURKA | |
| SCHEMBL28949767 | 0.82 | ALK (0.48) | ALKINSRIGF1RMAP4K1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118302430-A | Mono-p-toluene sulfonate and crystal forms of AXL kinase inhibitor | 南京正大天晴制药有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118251400-A | Salts of AXL kinase inhibitors, methods of preparation and uses thereof | 南京正大天晴制药有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| WO-2023093859-A1 | SALT OF AXL KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 南京正大天晴制药有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2023093861-A1 | MONO-P-TOLUENESULFONATE OF AXL KINASE INHIBITOR AND CRYSTAL FORM THEREOF | 南京正大天晴制药有限公司 | 2023-06-01 | — | — | WO | disclosed |
| CN-116178434-A | Mono-p-toluene sulfonate and crystal forms of AXL kinase inhibitor | 南京正大天晴制药有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-116178433-A | Salts of AXL kinase inhibitors, methods of preparation and use thereof | 南京正大天晴制药有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-115697993-A | Pyrimidines as AXL inhibitors | 南京正大天晴制药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021239133-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | 南京正大天晴制药有限公司 | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | AXL, FLT3, TYMP | ALK 87/4885INSR 1450/4885IGF1R 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.